I’m perfectly happy with my mid-tier Chase Sapphire Preferred® Card, and I didn’t expect to find myself with another premium Chase card. I had the Chase Sapphire Reserve® years ago, downgraded it, and figured I’d never need it again.However, once the new Sapphire Reserve for Business℠ (and its massive 200,000-point welcome offer) was brought into the market this past summer, it definitely made me rethink my strategy.As a small business owner with big World of Hyatt plans next year — including a family vacat ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Panoro Minerals Ltd. (“Panoro” or the “Company”) (TSX.V: PML) is pleased to announce the closing of the second and final tranche (the “Second Tranche”) of its previously announced “best efforts” private placement (the “Offering”) for gross proceeds of C$520,000 from the sale of 1,300,000 units of the Company (each, a “Unit”) at a price of C$0.40 pe ...

Core Insights - Lexaria Bioscience Corp. has successfully achieved its primary endpoint in the Phase 1b study GLP-1-H24-4, demonstrating significant efficacy in reducing unwanted side effects compared to Rybelsus® [2][13] - The company raised a total of $7.5 million through financing activities, which will support new development opportunities throughout 2026 [2][18] - The study results indicate that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus® [4][6] Study Results - All four DehydraTECH (DHT) test articles were found to be safe and well-tolerated, meeting the primary endpoint objective [3][13] - The total adverse events (AEs) for DHT-semaglutide were reduced by 47.9% compared to Rybelsus®, with a statistically significant reduction in gastrointestinal AEs [6][10] - The study included 126 participants, focusing on safety and tolerability, with DHT-semaglutide showing the best performance among the tested formulations [19] Efficacy Assessments - The primary efficacy endpoint of HbA1c reduction showed comparable performance between DHT-semaglutide and Rybelsus®, with no statistically significant difference [10][11] - Bodyweight reduction was more pronounced in the Rybelsus® control arm compared to all DHT arms, raising questions about the differing results [11][12] - The study's findings suggest that even small reductions in HbA1c can improve cardiovascular outcomes in overweight or obese individuals [10] Future Directions - Lexaria plans to investigate the DHT-semaglutide formulation further, potentially incorporating salcaprozate sodium (SNAC) in future studies [14][15] - The company aims to relay the study dataset to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026 [16][17] - Additional non-primary endpoint results are expected to be released soon, providing further insights into the study's findings [20]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

We are awaiting GDP data this morning. Final real day of data before everyone leaves and goes home for the Christmas holiday. Although we need to point out that this data is going to be stale.Remember, we didn't get it in time because of the longest government shutdown in history. And actually, what we're getting to, Matt, as you can see, is reaction here. A massive upside surprise.Prior was 3.8%. Their survey was 3.3%. GDP comes in at 4.3% this morning, Matt.That is an uptick not many people were expecting ...

Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).The update is regarding brilaroxazine, a novel serotonin-dopamine and neuroinflammatory signaling modulator, in late-stage development for schizophrenia.In written feedback, the FDA recommended a second Phase 3 clinical trial for brilaroxazine in patients with schizophrenia to, among other things, generate addition ...

Hyundai Motor Company on Tuesday announced a global partnership with the International Cricket Council (ICC), becoming a premier partner for six prestigious tournaments from 2026 to 2027.As a premier partner, the South Korean automaker secures exclusive rights and opportunities for the ICC’s upcoming international cricket calendar, including the Men’s Cricket World Cup 2027.“It’s a very good opportunity for us. It’s a very big association. Although Hyundai has associated with Cricket for the last 20 years, ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

MGM China extends the right to use "MGM" name through the 2032 Concession term with an automatic extension if a further Concession is granted or awarded MGM Resorts International (NYSE: MGM) is an S&P 500® global gaming and entertainment company with national and international locations featuring best-in-class hotels and casinos, state-of-the-art meetings and conference spaces, incredible live and theatrical entertainment experiences, and an extensive array of restaurant, nightlife and retail offerings. MGM ...

David focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. He is a long term investor of quality stocks and uses options for strategy. David told investors to buy in March 2009 at the bottom of the financial crisis. The S&P 500 increased 367% and the Nasdaq increased 685% from 2009 through 2019. He wants to help make people money by investing in high-quality growth stocks.Analyst’s Disclosure:I/we have no stock, option or similar derivative p ...